3177 results for «372»

Filter By

3177 results

Ultrasound renal denervation is now guideline-recommended: how do I get started?

20 May 2025 – From EuroPCR 2025

Ultrasound renal denervation (uRDN) is now guideline-recommended—are you ready to bring it into practice? This EuroPCR 2025 session offers everything you need to get started: review key results from Sham-controlled and off-medication trials confirming the efficacy and safety of RDN; understand why both the ESC and...

Ultrasound renal denervation is now guideline-recommended: how do I get started?

Valve choice - Shaping index procedures and lifetime patient management

22 May 2025 – From EuroPCR 2025

This session addresses recent advancements and ongoing challenges in transcatheter aortic valve implantation (TAVI), with a particular focus on valve selection during index procedures. Presentations include data from the Accurate IDE trial, highlighting the prognostic implications of valve underexpansion. A clinical case involving an 80-year-old patient with severe...

Valve choice - Shaping index procedures and lifetime patient management

Complex PCI in calcific coronary artery disease - LIVE Case

20 May 2025 – From EuroPCR 2025

A 76-year-old male patient presented with a significant history of coronary artery disease: CABG with LIMA/LAD and RIMA/OM (1996), RCA PCI with BVS (2016), OM PCI (2017), RIMA occlusion and OM retenosis treated with DCB (2022) with preserved LV. He was admitted for pre-operative evaluation prior...

Complex PCI in calcific coronary artery disease - LIVE Case

Why should laser atherectomy be part of your complex PCI algorithm?

21 May 2025 – From EuroPCR 2025

Watch this EuroPCR 2025 session to see how ELCA can make the difference in two challenging cases: a severely calcified, undilatable lesion, and an uncrossable one. Learn how pre- and peri-procedural imaging (CT, IVUS, OCT) supports tailored decision-making, and how ELCA enables safe and effective lesion...

Why should laser atherectomy be part of your complex PCI algorithm?

How to manage coronary artery disease in TAVI candidates?

20 May 2025 – From EuroPCR 2025

Understand the comprehensive management of coronary artery disease (CAD) in patients undergoing transcatheter aortic valve implantation (TAVI). This session reviews evidence-based evaluation, decision-making, and treatment strategies for significant coronary lesions, including severe left main and multivessel disease, illustrated through detailed case studies.

How to manage coronary artery disease in TAVI candidates?

How a new generation of coronary sinus reducer can significantly expand treatment options for patients with coronary microvascular dysfunction

21 May 2025 – From EuroPCR 2025

Discover the latest on managing coronary microvascular dysfunction (CMD) with insights from EuroPCR 2025. This session explores how physiology testing helps identify CMD endotypes in the cathlab and highlights the limitations of ETT for patients experiencing angina or dyspnea at rest. Learn about the A-FLUX coronary...

How a new generation of coronary sinus reducer can significantly expand treatment options for patients with coronary microvascular dysfunction

Role of imaging in ACS: from non-invasive to invasive investigations

20 May 2025 – From EuroPCR 2025

Explore the critical role of imaging in acute coronary syndrome (ACS) from non-invasive coronary CT angiography to invasive intracoronary imaging modalities. This session covers detection of culprit lesions, diagnostic strategies, and PCI optimization through real-world case examples.

Role of imaging in ACS: from non-invasive to invasive investigations

Mitral hotline: new devices

20 May 2025 – From EuroPCR 2025

Stay updated on emerging devices in mitral valve repair and replacement with this session covering novel technologies including transcatheter edge-to-edge repair (TEER), posterior leaflet restoration, transfemoral mitral annuloplasty, and a first-in-human transseptal TMVR system. Clinical trial data and early feasibility experiences provide valuable insights into advancing...

Mitral hotline: new devices

Mitral and tricuspid hotline: long-term outcomes

20 May 2025 – From EuroPCR 2025

Review long-term outcomes of transcatheter edge-to-edge repair (TEER) for mitral and tricuspid valve disease in this session. Highlights include pivotal trial results, mortality risk prediction tools, management of procedural failures, and real-world data, providing comprehensive insights into patient prognosis and therapeutic impact.

Mitral and tricuspid hotline: long-term outcomes

Imaging skills for successful TAVI procedure

21 May 2025 – From EuroPCR 2025

Enhance your imaging skills essential for successful TAVI procedures. This session covers complex scenarios such as left circumflex coronary artery anomalies, valve infolding risks with new platforms, bioprosthesis dysfunctions, procedural adaptations when faced with challenges, and zero-contrast TAVI techniques.

Imaging skills for successful TAVI procedure

Advancing the standard of care in PCI with Bioadaptor: from simple to complex

21 May 2025 – From EuroPCR 2025

This session provides an in-depth overview of Bioadapter technology and its potential to overcome the limitations of current drug-eluting stents (DES) in percutaneous coronary intervention (PCI). Speakers present data from recent trials, including the Bioadapter RCT and the Infinity Sweetheart study, demonstrating a reduction in target lesion...

Advancing the standard of care in PCI with Bioadaptor: from simple to complex

Coronary sinus reducer for microvascular angina

28 Feb 2020

A 61-year-old man with a history of 2-vessel coronary artery stenting, hypertension and type-2 diabetes mellitus was admitted 5 times within September 2017 and November 2018 for recurrent angina CCS class III-IV refractory to therapy with nitrates, b-blockers and ranolazine in maximally tolerated doses...

Coronary sinus reducer for microvascular angina

OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease

04 Nov 2021

Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
OPTIMUM: Early Outcomes From a Prospective Registry of PCI in Patients at Prohibitive Risk for CABG

Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation – The WATCH-TAVR Trial

26 Oct 2023

Panos Xaplanteris provides his take on WATCH-TAVR results which were presented by Samir R. Kapadia at TCT Congress 2023.

Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - The WATCH TAVR Trial

Panagiotis Xaplanteris

Author

Panagiotis Xaplanteris
Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - The WATCH TAVR Trial

The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis

22 Mar 2022

Daniele Giacoppo analyses the main results of the FLAVOUR trial which were presented by Bon-Kwon Koo, from Seoul National University Hospital, South Korea at the American College of Cardiology 2022. 

Daniele Giacoppo

Author

Daniele Giacoppo
The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis

Five-year outcomes of the randomised trial of fractional flow reserve guided PCI compared to coronary artery bypass grafting: FAME 3

02 Apr 2025

Kalaivani Mahadevan provides her take on the five-year outcomes of the FAME 3 trial presented by William F. Fearon at ACC.25 in Chicago.

Kalaivani Mahadevan

Author

Kalaivani Mahadevan
FFR-guided PCI vs CABG: 5-year results of the FAME 3 trial

Harmonising optimal strategy for treatment of coronary artery diseases – bleeding risk: HOST-BR

29 Mar 2025

Daniele Giacoppo and Nicola Ammirabile provide their take on the main results of the HOST-BR trial, presented by Hyo-Soo Kim at ACC.25 in Chicago.

Nicola Ammirabile

Author

Nicola Ammirabile
Daniele Giacoppo

Author

Daniele Giacoppo
Harmonising optimal strategy for treatment of coronary artery diseases – bleeding risk: HOST-BR
Didn’t find what you were looking for?